

DynaMed

The Evidence Based Clinical Database

每日更新主題評論實證醫學資料庫

EBSCO 廖婉如

DynaMed 實證醫學主題評論資料庫

- 市面唯一「每日更新」的EBM 主題評論資料庫
- 完整的實證等級資訊與實證文獻參考來源
- 條列式、架構化的主題內容呈現方式
- 可依照足以改變臨床決策的更新文獻進行篩選
- 提供無須額外付費且不限人次的行動裝置版本

Journal of Clinical Epidemiology (臨床傳染病學期刊)

評估市面上10種實證醫學資源 , 2012年12月份

- 在 Journal of Clinical Epidemiology (臨床傳染病期刊)所進行的一項研究中,DynaMed在10種實證醫學資源中,獲得了最高的評價。
- 1. Timeliness of content updating: 內容的更新 (DynaMed 獲評為 No.1)
- 2. Breadth of coverage: 內容的廣度 (DynaMed 獲評為No.3)
- 3. Quality of evidence reporting: 實證證據的品質 (DynaMed獲評為No.2)
- DynaMed 是唯一一項實證醫學資源于上述三項評選項目中 皆獲得前三名的實證醫學資料庫

Control for the second first have a

<u>Speed of updating online evidence based point of care summaries:</u> Prospective Cohort Analysis



From BMJ 2011;343:d5856 doi: 10.1136/bmj.d5856

Summary	At 3 months (%)	At 6 months (%)	At 9 months (%)	HR (95% CI)
Dynamed	77	84	87	Reference
EBM Guidelines	18	31	41	0.22 (0.17 to 0.29)
UpToDate	23	27	29	0.14 (0.09 to 0.21)
eMedicine	7	9	12	0.05 (0.03 to 0.09)
Clinical Evidence	0	1	4	0.03 (0.01 to 0.05)

從一篇系統性綜論(Systematic Review)刊登到被這些資源引用的平均速度如下:

- DynaMed 2個月
- EBM guideline 10個月
- 其他 (UpToDate, eMedicine, Clinical Evidence) 超過追蹤時間,無法計算。

資訊來源

每日審視逾500種+的頂尖醫學期刊、重要醫學二次文獻、 實證醫學文獻資源、藥物資訊資源、臨床診療指引






BMC Clinical Pharmacology



Cochrane Database of Systematic Reviews



Annals of Family Medicine


American Family Physician

http://www.dynamicmedical.com/sources.php

每日即時更新

Home | Recent Updates | E-Newsletter | Mobile | Calculators ∨ Help





提供以病患為導向的資訊 Patient-oriented outcomes

提供容易判讀的實證等級 (summary by FACT)

Level of Evidence:

Level 1 (likely reliable) Evidence

Level 2 (mid-level) Evidence

Level 3 (lacking direct) Evidence

提供容易判讀的建議等級(Summary by Guidelines)

Recommendations:

Grade A recommendation (consistent high-quality evidence)

Grade B recommendation (inconsistent or limited evidence)

Grade C recommendation (lacking direct evidence)

http://www.dynamicmedical.com/levels.php

DynaMed 實證等級之說明

- Level 1 (likely reliable) evidence
- 最有效之報告(以病患導向為主的結論),例:以RCT為主之實驗結果 (有效追蹤達80%以上)、來自世代研究初期(inception cohort studies)的 預後信息(prognostic information)、系統性文獻回顧所得之結果。
- Level 2 (mid-level) evidence
- 以病患導向為主的結論而產生的報告,且以科學化的檢視為方法,但是還未到level 1 的標準。例如有效追蹤低於80%的RCT、非隨機對照實驗的研究方式、缺乏足夠參考標準的診斷研究。Level 2並不代表可靠的證據等級。例如荷爾蒙補充療法在大多數的世代研究中都顯示可以降低心血管疾病的發生,但在許多的屬於LEVEL 1等級的RCT實驗中,此一療法不但無法預防心血管疾病,甚至有還可能會增加心血管疾病的風險。
- Level 3 (lacking direct) evidence 非科學化的分析研究且不是以病患為導向的結論報告, 例如: 病例報告、專家意見、及缺乏科學根據的推論。

Achilles tendinopathy

Treatment overview:

- rest and ice considered first-line therapy for acute Achilles tendinopathy (grade C recommendation [lacking direct evidence])
- if complete or partial runture non-weight hearing, immediate orthogodic consult, see Achilles tendon rupture
- · conservati 會證等級答訊
 - · res 貝迅守纵貝可
 - analgesics may reduce symptoms in the state term but do ... have long-term benefit
 - topical NSAID (niflumic acid) might reduct pain and hasten return a jour level of activity (level 2 [mid-level] evidence)
 - oral NSAIDs may be no better an placebo for improving pain and function (level 2 [mid-level] evidence)
 - also consider ice and elevation after ctivity
- calf stretching and strengthening exerci
 - necessary for recovery of function after conservative treatment
 - eccentric calf muscle training pears more effective than concentric calf muscle training (and watchful waiting) for recovery of function tendinosis (level 2 [mid-level] evidence)
- additional treatment considerations
 - topical glyceryl trinitrate plus physical therapy may reduce symptoms compared to physical therapy alone for chronic noninsertional achi evidence)
 - steroid injection not recommended due to limited inconsistent evidence (grade B recommendation [inconsistent or limited evidence])
 - shock wave therapy has inconsistent evidence for effect on pain in chronic Achilles tendinopathy
 - insufficient evidence to clearly define optimal treatment for acute or chronic Achilles tendonitis, based on Cochrane review of 9 trials

Activity:

Rest, ice and activity modification:

- rest and ice considered first-line therapy for acute Achilles tendinopathy (grade C recommendation [lacking direct evidence])
 - based on expert opinion
 - Reference J Fam Pract 2008 Apr;57(4):261 EBSCO host Full Text
- rest

Achilles tendinopathy

Treatment overview:

- rest and ice considered first-line therapy for acute Achilles tendinopathy (grade C recommendation [lacking direct evidence])
- if complete or partial rupture non-weight bearing, immediate

conconcitive treatment for 4.6 weeks if acute symptom adema

建議等級資訊

hes

- t do not have long-term benefit
- topical NSAID iffumic accomight reduct pain and hasten return to previous level of activity (level 2 [mid-level] evidence)
- oral NSAIDs may no better an placebo for improving pain and function (level 2 [mid-level] evidence)
- also consider ice and elevath. after activity
- calf stretching and strengthening exercises
 - necessary for recovery of function ter conservation treatment
 - eccentric calf muscle training appears three effective the concentric calf muscle training (and watchful waiting) for recovery of function tendinosis (level 2 [mid-level] evidence)
- additional treatment considerations
 - topical glyceryl trinitrate plus physical therapy in reduce symptom impared to physical therapy alone for chronic noninsertional achievidence)
 - steroid injection not recommended due to limited inclusive sistent evidence (grade B recommendation [inconsistent or limited evidence])
 - shock wave therapy has inconsistent evidence for effect pain in chronic Achilles tendinopathy
 - insufficient evidence to clearly define optimal treatment for the or chronic Achilles tendonitis, based on Cochrane review of 9 trials

Activity:

Rest, ice and activity modification:

- rest and ice considered first-line therapy for acute Achilles tendinopathy (grade C recommendation [lacking direct evidence])
 - based on expert opinion
 - Reference J Fam Pract 2008 Apr;57(4):261 EBSCO host Full Text
- rest

提供3,200個臨床的主題性標題

Offer clinically-organized summaries for nearly 3,000 topics

DynaMed Topics範例

- 一般與異常的疾病或是症狀(Chest Pain)
- 特定議題 (例:Avian Influenza, SARS)
- 正在發展的最新研究或範疇(例: 阿司匹林可降低心臟病及女性癌症罹患率)
- 使用DynaMed的醫生或是專業人員的建議

同時可查詢的正在開發中的標題(in process)

新標題可能來自於DynaMed內部討團隊討論、讀者建議或是其他可能的優秀作者。

http://www.dynamicmedical.com/organization.php

DynaMed 疾病主題的內容分類

- Description (including ICD-9 Codes) 描述
- Causes and Risk Factors 造成及風險因數
- Complications and Associated Conditions 併發症與相關症狀
- History
- Physical
- Diagnosis (提供實證等級資訊) 診斷
- Prognosis (提供實證等級資訊) 預後
- Treatment (提供實證等級資訊) 治療
- Prevention and Screening (提供實證等級資訊) 預防及篩選
- References (including Reviews and Guidelines) 參考資訊
- Patient Information 病患教育

Recent Updates | E-Newsletter | Mobile | Calculators >



Home

Search

點選滑鼠兩次 即可獲取所需資訊

Expand All

Top General Information (including ICD-9/-10 Codes) Causes and Risk Factors Complications and Associated Conditions History Physical Diagnosis Prognosis □ Treatment Treatment overview Activity Medications Surgery Consultation and referral Other management

Send Comment to Editor

Achilles tendinopathy

- 54 patients aged 18-70 years with chronic tendinopathy 2-7 cm above Achilles tendon insertion randomized to (saline injection plus usual care)
- pain and activity level score at 24 weeks improved significantly in both groups (not significantly different between the pain and activity level score at 24 weeks improved significantly in both groups (not significantly different between the pain and activity level score at 24 weeks improved significantly in both groups (not significantly different between the pain and activity level score at 24 weeks improved significantly in both groups (not significantly different between the pain and activity level score at 24 weeks improved significantly in both groups (not significantly different between the pain and activity level score at 24 weeks improved significantly in both groups (not significantly different between the pain and activity level score at 24 weeks improved significantly in both groups (not significantly different between the pain and activity level score at 24 weeks improved significantly in both groups (not significantly different between the pain and activity different between the pain activity different between the pain and activity different between the pain activity different betwe
- Reference JAMA 2010 Jan 13;303(2):144, commentary can be found in JAMA 2010 May 5;303(17):1696

Surgery:

- last resort for patients with chronic Achilles tendon pain unrelieved by nonoperative treatment
- surgeries include
 - · resection of prominent tuberosity
 - debridement of bursa
 - · excision of thickened, scarred paratenon
 - removal of accessible calcific deposits within tendon
- surgery reported to be beneficial (level 3 [lacking direct] evidence)
 - based on uncontrolled case series
 - retrospective study of 35 patients with painful Achilles tendon syndrome unrelieved by nonoperative treatmen years
 - mean pain scores improved from 4.7 preoperatively to 1.5 postoperatively, 90% patients had significant improved participation
 - 14 patients had altered sensation at surgical scar
 - Reference Am J Sports Med 2002 May-Jun;30(3):318 in J Musculoskel Med 2002 Dec;19(12):516

Consultation and referral:

- physical therapy in selected cases for muscle rehabilitation
 - · ultrasound modality, commonly used prior to manually-assisted calf and Achilles stretching
 - · transverse friction massage may convert tendinosis to tendonitis and initiate acute-phase immune response
- if complete or partial rupture non-weight bearing, immediate orthopedic consult

Other management:

insufficient evidence to clearly define optimal treatment for acute or chronic Achilles tendonitis

DynaMed 中的藥物資訊來源 Information Structure for AHFS Drug topic

- Warnings (if applicable) 警示
- General Information 一般資訊
- Uses and Efficacy 效用
- Dosage and Administration 藥劑與管理用法
- Cautions 用藥須知
- Drug Interactions 藥物交互作用
- Mechanisms of Actions/Pharmacokinetics 藥物動力學
- Stability 穩定度
- Preparation 藥劑
- Patient Information 病患須知
- References 參考文獻

Home

Expand All

Vasopressin

Geriatric Use:

Geriatric patients are particularly sensitive to vasopressin's effects; exercise caution. ¹⁵⁴

Contraindications:

Back ■ 1 of 1

- Chronic nephritis accompanied by nitrogen retention, until reasonable nitrogen concentrations are attained.
- History of anaphylaxis or other hypersensitivity to vasopressin of any component in the formulation. b

Common Adverse Effects:

Adverse effects associated with low doses are infrequent and mild, but increase in frequency and severity with high dose

Common adverse effects include circumoral pallor, sweating, tremor, pounding in the head, abdominal cramps, passage of diarrhea, intestinal hyperactivity, and uterine cramps may occur. ¹⁵⁴

Patients can be advised that some of these effects (e.g., blanching of the skin, abdominal cramps, nausea) may be mining administration. 154

▼ Interactions

Specific Drugs:

opeand brags.				
Drug	Interaction			
Alcohol	May block the antidiuretic activity of vasopressin in varying degrees $^{155}\mathrm{a}$			
Antidepressants, tricyclic	May potentiate the antidiuretic response to vasopressin ¹⁵⁵ a			
Carbamazepine	May potentiate the antidiuretic response to vasopressin ¹⁵⁵ a			
Chlorpropamide	May potentiate the antidiuretic response to vasopressin ¹⁵⁵ a			
Clofibrate	May potentiate the antidiuretic response to vasopressin ¹⁵⁵ a			

Top ■ FDA Recall ■ General Information ■ Uses and Efficacy ■ Dosage and

Cautions and Adverse
 Effects
 Warnings/Precautions


Administration

- Contraindications
 Common Adverse
 Effects
- ■ Interactions
- Mechanism of
 Action/Pharmacokinetics
- Stability and Compatibility
- Patient Information
- Acknowledgements

Send Comment to Editor

DynaMed 行動裝置版本

- DynaMed 訂戶即可免費使用
- 不限人次的行動裝置版本
- 支援以下行動裝置系統:
 - BlackBerry
 - iPhone & iPod Touch
 - Android
 - Windows Smartphone













with Apple APP & Android APP



Home

alopecia

Browse: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search



Browse Categories



利用關鍵字查找

1-50 of 134 Page: 1 2 3 Next

Alopecia areata	③	Alopecia areata
Androgenetic alopecia - work in progress	(E)	General Information (including ICD-9/-10 Codes)
Minoxidil (Topical)	(3)	Causes and Risk Factors
Finasteride	(3)	Complications and Associated Conditions
Toxicities of chemotherapeutic agents	(3)	History
Minoxidil (Systemic)	(b)	Physical Diagnosis
Discoid lupus erythematosus	0	Prognosis
Tinea capitis	(3)	☐ Treatment
Temozolomide	(3)	Treatment overview
Chemotherapy for advanced or recurrent non-small cell lung cancer (NSCLC)	(B)	Medications Medications
Trichotillomania	③	Consultation and referral Other management
Irinotecan	(3)	Prevention and Screening
Pentosan	(3)	References including Reviews and Guidelines
Gastric lymphoma	(D)	Patient Information
Polycystic ovary syndrome	③	Acknowledgements
Chronic mucocutaneous candidiasis	(3)	
Acne	(D)	
Hepatitis B	0	

Alopecia areata

治療方式說明

Treatment overview:

- usually no treatment indicated or necessary
- efalizumab (Raptiva) 1-2 mg/kg subcutaneously weekly (withdrawn from market in United States and European Union)

Medications:

- inconclusive evidence on topical and systemic interventions for alopecia
 - based on Cochrane review of trials with methodologic limitations
 - systematic review of 17 randomized trials evaluating topical and systemic interventions for alopecia areata, alopecia
 - most trials were small, only 1 trial had adequate allocation concealment, 2 trials reported use of intention-to-treat-a
 - interventions included topical and oral corticosteroids, topical cyclosporine, photodynamic therapy and topical minox
 - no intervention showed significant treatment benefit in terms of hair growth compared to placebo
 - no trial evaluated self-assessed hair growth or quality of life
 - no randomized trials identified that evaluated diphencyprone, dinitrochlorobenzene, intralesional corticosteroids, or of
 - Reference Cochrane Database Syst Rev 2008 Apr 16;(2):CD004413 EBSCO host Full Text
- intralesional steroids
- avoid systemic steroids
- PUVA and anthralin (irritation) have also been used
- minoxidil not generally recommended
- topical diphenylcyclopropenone reported to have about 45% to 79% response rates in case series (level 3 [lacking direction])
 - topical diphenylcyclopropenone reported to have 45% response rate at 6 months (25 patients had complete regro patients with chronic extensive alopecia areata (J Am Acad Dermatol 2001 Jan;44(1):73)
 - topical diphenylcyclopropenone reported to have 79% response rate (6 complete and 16 partial responders) in operate, 13 of 22 responders (51%) had partial recurrence over 6-12 months; side effects included eczematous reaction, and hyperpigmentation (BMC Dermatology 2005 May 26;5:6)
 - diphenylcyclopropenone (diphencyprone) associated with 78% cumulative response rate at 32 months in series of 3 JAMA 2001 Nov 21;286(19):2384)
- efalizumab may not be effective for alopecia areata (level 2 [mid-level] evidence)
 - based on small randomized trial



alopecia

Browse: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Browse Categories

分科查詢

Browse by Category:

- Allergic Disorders
- ☐ Cardiovascular Disorders
 - ■ Cardiovascular disease prevention
 - ☐ Cardiovascular medications
 - ★ ACE inhibitors

 - Antianginal agents
 - Antiarrhythmic agents
 - Anticoagulation
 - Antihypertensive agents
 - Antilipemic agents


 - Beta blockers
 - Acebutolol Rx
 - Atenolol Rx
 - Beta blockers during acute ST-elevation myocardial infarction (STEMI)
 - Beta blockers for heart failure
 - Betaxolol (Systemic) Rx
 - Bisoprolol Rx
 - Carvedilol Rx
 - Esmolol Rx
 - Labotalal Dv

ells palsy


Search

TAIPEI CITY HOSPITAL






HO	me Recent Updates E-Newsletter Mo	bile Calculators >
[DynaMed alopecia Browse: A B C D I	Search ② EFGHIJKLMNOPQRSTUVWXYZ Browse Categories
	1-50 of 500 Page: 1 2 3 4 5 >	Limit by Category: Cardiovascular Disorders /大 日本 手》 무미 各年 沙巴
	Topic	Wind Reason
	Medications before, during and after percutaneous coronary intervention	review of management of bleeding complications in patients
	Antiplatelet and anticoagulant drugs for acute coronary syndrome	addition of apixaban to standard antiplatelet therapy increases major bleeding events (N Engl J Med 2011 Jul 2
	Anticoagulation for coronary artery disease	addition of dabigatran to dual antiplatelet therapy may increase bleeding in patients with recent acute corona early online)
	Bivalirudin	NICE guidance on bivalirudin for treatment of ST-segment elevation myocardial infarction (STEMI) (NICE 2011
	Hypercholesterolemia	fasting may have clinically insignificant effect on measurements of total, LDL and HDL cholesterol in children (P
	Acute coronary syndrome	hypoperfusion on contrast echocardiography may predict angiographically severe coronary artery disease (CAD myocardial infarction (NSTEMI) awaiting coronary angiography (Am J Cardiol 2011 May 1)
	Infective endocarditis	ACR guideline on suspected bacterial endocarditis (National Guideline Clearinghouse 2011 Aug 1)



醫學計算公式



DynaMed 與下列電子病歷 EMR(Electronic Medical Record)系統完整結合



MEDITECH









GE Healthcare





範例: Acute Appendicitis此主題與 EMR系統結合的畫面

